927 related articles for article (PubMed ID: 29415801)
21. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.
Sanders-van Wijk S; van Empel V; Davarzani N; Maeder MT; Handschin R; Pfisterer ME; Brunner-La Rocca HP;
Eur J Heart Fail; 2015 Oct; 17(10):1006-14. PubMed ID: 26472682
[TBL] [Abstract][Full Text] [Related]
22. Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure.
Pascual-Figal DA; Ferrero-Gregori A; Gomez-Otero I; Vazquez R; Delgado-Jimenez J; Alvarez-Garcia J; Gimeno-Blanes JR; Worner-Diz F; Bardají A; Alonso-Pulpon L; Gonzalez-Juanatey JR; Cinca J;
Int J Cardiol; 2017 Aug; 240():265-270. PubMed ID: 28318662
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups.
Martinsson A; Oest P; Wiborg MB; Reitan Ö; Smith JG
Scand Cardiovasc J; 2018 Aug; 52(4):205-210. PubMed ID: 29656687
[TBL] [Abstract][Full Text] [Related]
24. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
[TBL] [Abstract][Full Text] [Related]
25. Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction.
Chen X; Savarese G; Dahlström U; Lund LH; Fu M
Clin Res Cardiol; 2019 Dec; 108(12):1394-1405. PubMed ID: 30980205
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
[TBL] [Abstract][Full Text] [Related]
27. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.
Tromp J; Khan MA; Klip IT; Meyer S; de Boer RA; Jaarsma T; Hillege H; van Veldhuisen DJ; van der Meer P; Voors AA
J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28360225
[TBL] [Abstract][Full Text] [Related]
28. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
29. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
30. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.
Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano GMC; Dahlström U; Lund LH
JACC Heart Fail; 2018 Mar; 6(3):246-256. PubMed ID: 29428439
[TBL] [Abstract][Full Text] [Related]
31. Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions.
Pan W; Yang D; Yu P; Yu H
BMC Cardiovasc Disord; 2020 Apr; 20(1):208. PubMed ID: 32354356
[TBL] [Abstract][Full Text] [Related]
32. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study.
Tsuji K; Sakata Y; Nochioka K; Miura M; Yamauchi T; Onose T; Abe R; Oikawa T; Kasahara S; Sato M; Shiroto T; Takahashi J; Miyata S; Shimokawa H;
Eur J Heart Fail; 2017 Oct; 19(10):1258-1269. PubMed ID: 28370829
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry.
Chioncel O; Lainscak M; Seferovic PM; Anker SD; Crespo-Leiro MG; Harjola VP; Parissis J; Laroche C; Piepoli MF; Fonseca C; Mebazaa A; Lund L; Ambrosio GA; Coats AJ; Ferrari R; Ruschitzka F; Maggioni AP; Filippatos G
Eur J Heart Fail; 2017 Dec; 19(12):1574-1585. PubMed ID: 28386917
[TBL] [Abstract][Full Text] [Related]
34. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
Löfman I; Szummer K; Dahlström U; Jernberg T; Lund LH
Eur J Heart Fail; 2017 Dec; 19(12):1606-1614. PubMed ID: 28371075
[TBL] [Abstract][Full Text] [Related]
35. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
[No Abstract] [Full Text] [Related]
36. Predictors and outcomes of heart failure with mid-range ejection fraction.
Bhambhani V; Kizer JR; Lima JAC; van der Harst P; Bahrami H; Nayor M; de Filippi CR; Enserro D; Blaha MJ; Cushman M; Wang TJ; Gansevoort RT; Fox CS; Gaggin HK; Kop WJ; Liu K; Vasan RS; Psaty BM; Lee DS; Brouwers FP; Hillege HL; Bartz TM; Benjamin EJ; Chan C; Allison M; Gardin JM; Januzzi JL; Levy D; Herrington DM; van Gilst WH; Bertoni AG; Larson MG; de Boer RA; Gottdiener JS; Shah SJ; Ho JE
Eur J Heart Fail; 2018 Apr; 20(4):651-659. PubMed ID: 29226491
[TBL] [Abstract][Full Text] [Related]
37. Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?
Fudim M; Kelly JP; Jones AD; AbouEzzeddine OF; Ambrosy AP; Greene SJ; Reddy YNV; Anstrom KJ; Alhanti B; Lewis GD; Hernandez AF; Felker GM
Am Heart J; 2020 Feb; 220():97-107. PubMed ID: 31805424
[TBL] [Abstract][Full Text] [Related]
38. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
[TBL] [Abstract][Full Text] [Related]
39. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
[TBL] [Abstract][Full Text] [Related]
40. Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction.
de Boer RA; Nayor M; deFilippi CR; Enserro D; Bhambhani V; Kizer JR; Blaha MJ; Brouwers FP; Cushman M; Lima JAC; Bahrami H; van der Harst P; Wang TJ; Gansevoort RT; Fox CS; Gaggin HK; Kop WJ; Liu K; Vasan RS; Psaty BM; Lee DS; Hillege HL; Bartz TM; Benjamin EJ; Chan C; Allison M; Gardin JM; Januzzi JL; Shah SJ; Levy D; Herrington DM; Larson MG; van Gilst WH; Gottdiener JS; Bertoni AG; Ho JE
JAMA Cardiol; 2018 Mar; 3(3):215-224. PubMed ID: 29322198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
